natgillin/translations-raw huggingface dataset:
They reduce the swelling and irritation in the small air passages in the lungs and so gradually ease breathing problems. 
Smanjuju oticanje i nadraženost malih dišnih putova u plućima i na taj način postupno ublažavaju tegobe s disanjem.
Moderate/ severe exacerbations were defined as worsening symptoms that required treatment with oral corticosteroids and/or antibiotics or in-patient hospitalisation. 
Umjerene/teške egzacerbacije definirane su kao pogoršanje simptoma koje je zahtijevalo liječenje peroralnim kortikosteroidima i/ili antibioticima ili hospitalizaciju.
The inhaler is packaged in a tray. 
Inhalator je zapakiran u podložak.
Animal studies showed no effect of fluticasone furoate/vilanterol trifenatate on fertility (see section 5.3). 
Ispitivanja na životinjama nisu ukazala na utjecaj flutikazonfuroata/vilanteroltrifenatata na plodnost (vidjeti dio 5.3).
Pneumonia (infection of the lung) (common side effect, may affect up to 1 in 10 people) Tell your doctor if you have any of the following while taking Relvar Ellipta - they could be symptoms of a lung infection: 
Upala pluća (infekcija pluća) (česta nuspojava, može se javiti u do 1 na 10 osoba) Obavijestite svog liječnika ako se pri primjeni lijeka Relvar Ellipta pojavi bilo koja od sljedećih nuspojava - može se raditi o simptomima infekcije pluća:
The incidence of cardiovascular history/risk factors was similar across the treatment groups with patients most commonly suffering from hypertension (46%), followed by hypercholesterolemia (29%) and diabetes mellitus (12%). 
Incidencija kardiovaskularnih bolesti/čimbenika rizika bila je slična u svim terapijskim skupinama, a bolesnici su najčešće patili od hipertenzije (46%), hiperkolesterolemije (29%) i šećerne bolesti (12%).
• inflammation of the lungs (bronchitis) 
• upala pluća (bronhitis)
Chronic obstructive pulmonary disease (COPD) is a serious, long term lung disease where the airways become inflamed and thickened. 
Kronična opstruktivna plućna bolest (KOPB) je ozbiljna i dugotrajna plućna bolest kod koje dišni putovi postaju upaljeni i zadebljani.
When you take the inhaler out of its tray, it will be in the ‘closed' position. 
Kad izvadite inhalator iz podloška, bit će u 'zatvorenom 'položaju.
The precise mechanism through which fluticasone furoate affects asthma and COPD symptoms is not known. 
Točan mehanizam djelovanja putem kojega flutikazonfuroat utječe na simptome astme i KOPB-a nije poznat.
Neither fluticasone furoate nor vilanterol trifenatate had any adverse effects on fertility or pre- and post-natal development in rats. 
Ni flutikazonfuroat ni vilanteroltrifenatat nisu imali štetne učinke na plodnost niti na prenatalni i postnatalni razvoj u štakora.
If you accidentally take more Relvar Ellipta than your doctor has instructed, talk to your doctor or pharmacist. 
Ako slučajno primijenite više lijeka Relvar Ellipta nego što Vam je liječnik rekao, obratite se svom liječniku ili ljekarniku.
This should be treated immediately with a short-acting inhaled bronchodilator. 
Stanje treba odmah liječiti kratkodjelujućim inhalacijskim bronhodilatatorom.
Don't open the tray until you are ready to start using your new inhaler. 
Nemojte otvarati podložak dok ne budete spremni početi koristiti svoj novi inhalator.
if you experience blurred vision or other visual disturbances. 
u slučaju zamućenog vida ili drugih poremećaja vida.
If you have been told by your doctor that you have an intolerance to some sugars, or to milk protein, contact your doctor before using this medicine. 
Ako Vam je liječnik rekao da ne podnosite neke šećere ili mliječne proteine, obratite se liječniku prije nego što primijenite ovaj lijek.
• awareness of heart beat (palpitations) 
• osjećaj lupanja srca (palpitacije)
Immediate breathing difficulties after using Relvar Ellipta are rare. 
Tegobe s disanjem neposredno nakon primjene lijeka Relvar Ellipta su rijetke.
Pneumonia in patients with asthma 
Pneumonija u bolesnika s astmom
Overall, across the two studies combined 2009 (62%) patients had cardiovascular history/risk factors at screening. 
Promatrajući oba ispitivanja zajedno, ukupno je 2009 (62%) bolesnika prilikom probira imalo kardiovaskularne bolesti u anamnezi/čimbenika rizika za te bolesti.
Vilanterol trifenatate was not teratogenic in rats. 
Vilanteroltrifenatat nije imao teratogen učinak u štakora.
If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids. 
Ako bolesnik ima simptome kao što su zamućen vid ili neke druge poremećaje vida, treba razmotriti potrebu da ga se uputi oftalmologu radi procjene mogućih uzroka, koji mogu uključivati kataraktu, glaukom ili rijetke bolesti kao što je centralna serozna korioretinopatija (CSCR) koja je zabilježena nakon sustavne i topikalne uporabe kortikosteroida.
Vilanterol belongs to a group of medicines called long acting bronchodilators. 
Vilanterol pripada skupini lijekova koje nazivamo dugodjelujućim bronhodilatatorima.
If you have moderate or severe liver disease, your doctor will limit your dose to the lower strength of Relvar Ellipta (92/22 micrograms once daily). 
Ako imate umjerenu ili tešku jetrenu bolest, Vaš liječnik će ograničiti dozu lijeka Relvar Ellipta na manju jačinu (92/22 mikrograma jedanput na dan).
Relvar Ellipta contains lactose 
Relvar Ellipta sadrži laktozu
Other medicines and Relvar Ellipta 
Drugi lijekovi i Relvar Ellipta
The increase in vilanterol exposure was not associated with an increase in beta2-agonist related systemic effects on heart rate, blood potassium or QTcF interval. 
Povećanje izloženosti vilanterolu nije bilo povezano s povećanjem sistemskih učinaka beta2-agonista na srčani ritam, razinu kalija u krvi niti QTcF interval.
If you use more Relvar Ellipta than you should 
Ako primijenite više lijeka Relvar Ellipta nego što ste trebali
Studies in subjects with mild, moderate and severe hepatic impairment showed an increase in systemic exposure to fluticasone furoate (both Cmax and AUC) (see section 5.2). 
Ispitivanja u ispitanika s blagim, umjerenim i teškim oštećenjem jetrene funkcije ukazala su na povećanje sistemske izloženosti flutikazonfuroatu (i Cmax i AUC) (vidjeti dio 5.2).
You do not need to prepare Relvar Ellipta in any special way, not even the first time you use it. 
Lijek Relvar Ellipta ne morate posebno pripremati za primjenu, čak ni kada ga koristite prvi puta.
The inhaler contains two aluminium foil laminate strips of 14 or 30 doses. 
Inhalator sadrži dvije trake od višeslojne aluminijske folije s 14 ili 30 doza.
The incidence of pneumonia in patients with asthma was common at the higher dose. 
Incidencija pneumonije u bolesnika s astmom bila je česta pri primjeni veće doze.
• voice disorders 
• glasovni poremećaji
LIST OF EXCIPIENTS Also contains lactose and magnesium stearate. 
POPIS POMOĆNIH TVARI Također sadrži laktozu i magnezijev stearat.
Fluticasone furoate is primarily metabolised through hydrolysis of the S-fluoromethyl carbothioate group to metabolites with significantly reduced corticosteroid activity. 
Flutikazonfuroat se prvenstveno metabolizira putem hidrolize skupine S-fluorometil karbotioata na metabolite sa značajno smanjenim kortikosteroidnim djelovanjem.
14 doses 30 doses 
14 doza 30 doza
If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary. 
Ako dođe do predoziranja, treba pratiti bolesnika i primijeniti odgovarajuće potporne mjere liječenja.
If the inhaler cover is opened and closed without inhaling the medicine, the dose will be lost. 
Ako se poklopac inhalatora otvori i zatvori bez inhaliranja lijeka, doza će se izgubiti.
In a placebo-controlled study in subjects with moderate COPD and a history of, or an increased risk of cardiovascular disease, there was no increase in the risk of cardiovascular events in patients receiving fluticasone furoate/vilanterol compared with placebo (see section 5.1). 
U placebom kontroliranom ispitivanju u bolesnika s umjerenim KOPB-om i kardiovaskularnom bolešću u anamnezi ili povećanim rizikom od kardiovaskularne bolesti, nije zabilježeno povećanje rizika od kardiovaskularnih događaja u bolesnika koji su uzimali flutikazonfuroat/vilanterol u usporedbi s onima koji su primali placebo (vidjeti dio 5.1).
• increased cough or increased breathing difficulties 
• pojačan kašalj ili otežano disanje
Pharmacological and toxicological effects seen with fluticasone furoate or vilanterol in nonclinical studies were those typically associated with either glucocorticoids or beta2-agonists. 
Farmakološki i toksikološki učinci zabilježeni kod primjene flutikazonfuroata ili vilanterola u nekliničkim ispitivanjima bili su oni koji se tipično povezuju s glukokortikoidima ili beta2-agonistima.
INFORMATION IN BRAILLE relvar ellipta 184:22 
16. PODACI NA BRAILLEOVOM PISMU relvar ellipta 184:22
Vilanterol is primarily metabolised by O-dealkylation to a range of metabolites with significantly reduced 1- and 2-agonist activity. 
Vilanterol se prvenstveno metabolizira putem O-dealkilacije na niz metabolita sa značajno smanjenim β1 i β2-agonističkim djelovanjem.
There have been reports of increases in blood glucose levels in diabetic patients and this should be considered when prescribing to patients with a history of diabetes mellitus. 
U bolesnika sa šećernom bolešću prijavljene su povećane razine glukoze u krvi pa to treba uzeti u obzir prilikom propisivanja lijeka bolesnicima sa šećernom bolešću u anamnezi.
Oral corticosteroids and antibiotics were allowed for the acute treatment of COPD exacerbations with specific guidelines for use. 
Primjena peroralnih kortikosteroida i antibiotika bila je dopuštena za akutno liječenje egzacerbacija KOPB-a, uz posebne smjernice za primjenu.
There is no relevant use of Relvar Ellipta in the paediatric population for the indication of COPD. 
Nije opravdana primjena lijeka Relvar Ellipta u pedijatrijskoj populaciji za indikaciju KOPB-a.
• weakening of the bones, leading to fractures 
• slabljenje kostiju koje izaziva prijelome • bol u trbuhu
You can also report side effects directly via the national reporting system listed in Appendix V . 
Nuspojave možete prijaviti izravno putem nacionalnog sustava za prijavu nuspojava: navedenog u Dodatku V.
Rinsing your mouth out with water immediately after using Relvar Ellipta may help stop this side effect developing. 
Ispiranje usta vodom odmah nakon primjene lijeka Relvar Ellipta može pomoći u sprječavanju pojave ove nuspojave.
There is no additional benefit of the 184/22 micrograms dose compared to the 92/22 micrograms dose and there is a potential increased risk of pneumonia and systemic corticosteroid-related adverse reactions (see sections 4.4 and 4.8). 
Nema dodatnih korisnih učinaka kod primjene doze od 184/22 mikrograma u odnosu na dozu od 92/22 mikrograma, ali postoji mogućnost povećanog rizika od pneumonije i nuspojava povezanih sa sistemskim djelovanjem kortikosteroida (vidjeti dijelove 4.4 i 4.8).
The medicine is now ready to be inhaled. 
Lijek je sada spreman za inhaliranje.
In HZA106837 all patients had at least one exacerbation that required treatment with oral corticosteroids in the year prior to visit 1. 
U ispitivanju HZA106837 svi su ispitanici imali barem jednu egzacerbaciju koja je zahtijevala liječenje peroralnim kortikosteroidima unutar godine dana prije 1. posjeta.
Each delivered dose contains approximately 25 mg of lactose (as monohydrate). 
Jedna primijenjena doza sadrži približno 25 mg laktoze (u obliku hidrata).
No dosage adjustment is necessary based on gender, weight or BMI. 
Nije potrebno prilagođavati dozu na temelju spola, tjelesne težine ili indeksa tjelesne mase.
Co-administration should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid undesirable effects, in which case patients should be monitored for systemic corticosteroid undesirable effects. 
Istodobnu primjenu treba izbjegavati, osim kada korist nadmašuje povećani rizik od neželjenih sistemskih učinaka kortikosteroida, a u tom slučaju je bolesnike potrebno pratiti radi otkrivanja neželjenih sistemskih učinaka kortikosteroida.
The inhaler is a multi-component device composed of polypropylene, high density polyethylene, polyoxymethylene, polybutylene terephthalate, acrylonitrile butadiene styrene, polycarbonate and stainless steel. 
Inhalator je višedijelni uređaj koji se sastoji od polipropilena, polietilena visoke gustoće, polioksimetilena, polibutilen tereftalata, akrilonitril butadien stirena, polikarbonata i nehrđajućeg čelika.
For an elderly subject (aged 84 years) with low bodyweight (35 kg) vilanterol AUC (0-24) is predicted to be 35% higher than the population estimate (subject with COPD aged 60 years and bodyweight of 70 kg), whilst Cmax was unchanged. 
U starijeg ispitanika (u dobi od 84 godine) male tjelesne težine (35 kg) predviđeni AUC(0-24) vilanterola je 35% viši od procijenjene vrijednosti za populaciju (ispitanik s KOPB-om u dobi od 60 godina i tjelesnom težinom od 70 kg), dok Cmax ostaje nepromijenjen.
If you have severe asthma, your doctor may decide that you should use one inhalation of the higher strength inhaler (184 micrograms fluticasone furoate and 22 micrograms of vilanterol). 
Ako imate tešku astmu, liječnik će možda donijeti odluku da morate primjenjivati jednu inhalaciju jačeg inhalatora (184 mikrograma flutikazonfuroata i 22 mikrograma vilanterola).
Fluticasone furoate/vilanterol should be administered with caution in patients with pulmonary tuberculosis or in patients with chronic or untreated infections. 
Flutikazonfuroat/vilanterol treba primjenjivati uz oprez u bolesnika s tuberkulozom pluća ili u bolesnika s kroničnim ili neliječenim infekcijama.
INFORMATION IN BRAILLE relvar ellipta 92:22 
16. PODACI NA BRAILLEOVOM PISMU relvar ellipta 92:22
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS TRAY LABEL 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP NALJEPNICA NA PODLOŠKU
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (Pharmacovigilance or risk minimisation) milestone being reached. 
• prilikom svake izmjene sustava za upravljanje rizikom, a naročito kada je ta izmjena rezultat primitka novih informacija koje mogu voditi ka značajnim izmjenama omjera korist/rizik,
Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. 
Svi inhalacijski kortikosteroidi mogu imati sistemske učinke, osobito ako se dugotrajno primjenjuju u velikim dozama.
There was no evidence for age (12-84) to affect the pharmacokinetics of fluticasone furoate and vilanterol in subjects with asthma. 
Nije dokazano da životna dob (12-84) utječe na farmakokinetiku flutikazonfuroata i vilanterola u ispitanika s astmom.
The oral bioavailability of both fluticasone furoate and vilanterol was low, on average 1.26% and <2%, respectively. 
Oralna bioraspoloživost flutikazonfuroata i vilanterola bila je niska, u prosjeku 1,26% odnosno <2%.
Your doctor may wish to monitor you carefully if you are taking any of these medicines as they may increase the side effects of Relvar Ellipta. 
Vaš liječnik će Vas možda htjeti pažljivo pratiti ako uzimate takve lijekove, jer oni mogu povećati nuspojave lijeka
It will only be effective as long as you are using it. Do not stop unless your doctor advises you to, even if you feel better. 
Nemojte prestati primjenjivati lijek, osim ako Vam to ne kaže liječnik, čak i ako se osjećate bolje.
If patients are inadequately controlled on Relvar Ellipta 92/22 micrograms, the dose can be increased to 184/22 micrograms, which may provide additional improvement in asthma control. 
Ako bolesnici nisu dobro kontrolirani lijekom Relvar Ellipta od 92/22 mikrograma, doza se može povećati na 184/22 mikrograma, što može dodatno poboljšati kontrolu astme.
What Relvar Ellipta looks like and contents of the pack The Ellipta device itself is a light grey inhaler with a yellow mouthpiece cover and a dose counter. 
Kako Relvar Ellipta izgleda i sadržaj pakiranja Sam uređaj Ellipta je svijetlosivi inhalator sa žutim poklopcem nastavka za usta i brojačem doza.
If symptoms arise in the period between doses, an inhaled, short-acting beta2-agonist should be used for immediate relief. 
Ako se simptomi pojave u razdoblju između primjene dviju doza, treba uzeti kratkodjelujući inhalacijski beta2-agonist za trenutno ublažavanje simptoma.
if you think the above applies to you, don't use Relvar Ellipta until you have checked with your doctor. 
• ako mislite da se gore navedeno odnosi na Vas, nemojte primjenjivati Relvar Ellipta dok se ne posavjetujete sa svojim liječnikom.
There is insufficient information on the excretion of fluticasone furoate or vilanterol trifenatate and/or metabolites in human milk. 
Nema dovoljno podataka o izlučivanju flutikazonfuroata ili vilanteroltrifenatata i/ili njihovih metabolita u majčino mlijeko.
The primary endpoint was all-cause mortality and a secondary endpoint was a composite of cardiovascular events (on-treatment cardiovascular death, myocardial infarction, stroke, unstable angina, or transient ischemic attack). 
Primarna mjera ishoda bila je smrt zbog bilo kojeg uzroka, dok su sekundarnu mjeru ishoda činili objedinjeni kardiovaskularni događaji (smrt tijekom liječenja zbog kardiovaskularnog uzroka, infarkt miokarda, moždani udar, nestabilna angina ili tranzitorna ishemijska ataka).
In vitro plasma protein binding in human plasma of fluticasone furoate and vilanterol was high, on average >99.6% and 93.9%, respectively. 
Stupanj vezivanja flutikazonfuroata i vilanterola za proteine u ljudskoj plazmi in vitro bio je visok, prosječno >99,6% za flutikazonfuroat odnosno 93,9% za vilanterol.
White powder in a light grey inhaler with a yellow mouthpiece cover and a dose counter. 
Bijeli prašak u svijetlosivom inhalatoru sa žutim poklopcem nastavka za usta i brojačem doza.
If you open and close the cover without inhaling the medicine, you will lose the dose. 
Ako otvorite i zatvorite poklopac inhalatora bez inhaliranja lijeka, izgubit ćete dozu.
Fluticasone furoate was not teratogenic in rats or rabbits, but delayed development in rats and caused abortion in rabbits at maternally toxic doses. 
Flutikazonfuroat nije imao teratogen učinak na štakore ni kuniće, ali je usporio razvoj u štakora i izazvao abortus u kunića pri primjeni doza toksičnih za skotne ženke.
What you need to know before you use Relvar Ellipta 
Što morate znati prije nego počnete primjenjivati Relvar Ellipta
An overdose of fluticasone furoate/vilanterol may produce signs and symptoms due to the individual component's actions, including those seen with overdose of other beta2-agonists and consistent with the known inhaled corticosteroid class effects (see section 4.4). 
Predoziranje flutikazonfuroatom/vilanterolom može izazvati znakove i simptome uslijed djelovanja pojedinih sastojaka lijeka, uključujući znakove i simptome zabilježene kod predoziranja drugim beta2-agonistima i sukladne poznatim učincima razreda inhalacijskih kortikosteroida (vidjeti dio 4.4).
HZC102970 and HZC102871 integrated 
HZC102970 i HZC102871 zajedno
When the inhaler is taken out of its tray, it will be in the ‘closed' position. 
Kada se inhalator izvadi iz podloška, nalazi se u 'zatvorenom' položaju.
Prior to randomization, subjects were required to discontinue previous COPD medications used at baseline, which included long-acting bronchodilators plus inhaled corticosteroids (28%), long-acting bronchodilators alone (11%) and inhaled corticosteroids alone (4%). 
Prije randomizacije ispitanici su morali prekinuti primjenu lijekova za KOPB koje su uzimali na početku ispitivanja, a koji su uključivali dugodjelujuće bronhodilatatore u kombinaciji s inhalacijskim kortikosteroidima (28%), samostalno primjenjivane dugodjelujuće bronhodilatatore (11%) i samostalno primjenjivane inhalacijske kortikosteroide (4%).
Caution is advised when co-administering with strong CYP 3A4 inhibitors (e.g. ketoconazole, ritonavir, cobicistat-containing products) as there is potential for increased systemic exposure to both fluticasone furoate and vilanterol. 
Preporučuje se oprez pri istodobnoj primjeni sa snažnim inhibitorima CYP 3A4 (npr. ketokonazolom, ritonavirom, lijekovima koji sadrže kobicistat) jer postoji mogućnost povećane sistemske izloženosti i flutikazonfuroatu i vilanterolu.
These were randomised controlled studies in patients with a clinical diagnosis of COPD. 
Navedena su ispitivanja bila randomizirana kontrolirana ispitivanja u bolesnika kojima je klinički dijagnosticiran KOPB.
All-cause mortality was: fluticasone furoate/vilanterol, 6.0%; placebo, 6.7%; fluticasone furoate, 6.1%; vilanterol, 6.4%. 
Smrt zbog bilo kojeg uzroka iznosila je 6,0% uz flutikazonfuroat/vilanterol, 6,7% uz placebo, 6,1% uz flutikazonfuroat te 6,4% uz vilanterol.
Interaction with P-glycoprotein inhibitors 
Interakcija s inhibitorima P-glikoproteina
Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. 
Flutikazonfuroat je sintetički trifluorirani kortikosteroid s jakim protuupalnim djelovanjem.
When you first use the Ellipta inhaler you do not need to check that it is working properly, and you do not need to prepare it for use in any special way. 
Kada koristite Ellipta inhalator po prvi puta, ne morate provjeravati radi li ispravno niti ga morate posebno pripremati za uporabu.
If you become wheezy or breathless, or develop any other symptoms of an asthma attack, use your quick-acting inhaler (e.g. salbutamol), then seek medical advice. 
Ako dođe do piskanja pri disanju, ako ostanete bez zraka ili ako se pojave drugi simptomi napadaja astme, primijenite brzodjelujući inhalacijski lijek (npr. salbutamol), a zatim zatražite savjet liječnika.
Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, growth retardation in children and adolescents, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). 
Mogući sistemski učinci uključuju Cushingov sindrom, Cushingoidni izgled, supresiju nadbubrežne žlijezde, smanjenje mineralne gustoće kostiju, usporen rast u djece i adolescenata, kataraktu i glaukom te rjeđe niz psiholoških pojava ili promjena u ponašanju, uključujući psihomotoričku hiperaktivnost, poremećaje spavanja, anksioznost, depresiju ili agresivnost (osobito u djece).
Close the inhaler and rinse your mouth Slide the cover upwards as far as it will go to cover the mouthpiece. 
Zatvorite inhalator i isperite usta • Povucite poklopac prema gore koliko ide kako biste prekrili nastavak za usta.
Clinical pharmacology studies with a specific P-gp inhibitor and fluticasone furoate have not been conducted. 
Nisu provedena klinička farmakološka ispitivanja sa specifičnim inhibitorom P-gp-a i flutikazonfuroatom.
The European Medicines Agency has deferred the obligation to submit the results of studies with Relvar Ellipta in one or more subsets of the paediatric population in asthma (see section 4.2 for information on paediatric use). 
Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja lijeka Relvar Ellipta u jednoj ili više podskupina pedijatrijske populacije u astmi (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Relvar Ellipta contains two active substances: fluticasone furoate and vilanterol. 
Relvar Ellipta sadrži dvije djelatne tvari: flutikazonfuroat i vilanterol.
1 inhaler of 14 doses 1 inhaler of 30 doses 
1 inhalator s 14 doza 1 inhalator s 30 doza
PHARMACEUTICAL PARTICULARS 6.1 List of excipients Lactose monohydrate Magnesium stearate 
6.1 Popis pomoćnih tvari laktoza hidrat magnezijev stearat